Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pfmoaa Toxicity topic
No spam. Unsubscribe anytime.
Board presses EPA for PFMOAA assessment; DEQ readies consent‑order studies for review
Summary
DEQ told the advisory board the EPA had completed an internal PFMOAA toxicity assessment but had not released the final report; DEQ requested the assessment and underlying modeling outputs, and offered new in‑house mammalian immunotoxicity reports (>1,000 pages each) for board review while it awaits EPA materials.
Frannie Nelson, environmental toxicologist and board liaison for DEQ, asked the science advisory board whether it had bandwidth to revisit a 2022 charge: determine whether available studies support deriving a point of departure for PFMOAA (a short‑chain PFAS prominent in DEQ’s consent‑order work).
"With these current studies, is there enough scientific support to identify a point of departure for deriving a reference dose for PFNYA?" Nelson asked the board, summarizing the charge and recent activity. She said EPA’s internal review was complete and that the office of research and development had taken the assessment to external review, but the final assessment remained unreleased; DEQ has requested the final document and, if the assessment cannot be released, the underlying weight‑of‑evidence analyses and modeling outputs.
Nelson reported that DEQ has received consent‑order mammalian toxicity reports (28‑day rodent immunotoxicity studies for rats and mice) and that those files run to more than 1,000 pages each; 90‑day studies are planned and will be informed by the 28‑day results. Board members recommended waiting briefly for EPA’s release but also asked DEQ to circulate the new papers and consent‑order study reports so members who wish to review them can do so. DEQ proposed a near‑term interim meeting in about two months to reassess status and to determine whether a state benchmark‑dose effort is needed if EPA’s assessment does not appear.
